Company Overview and News

29
AGNC Investment's Q3 2018 Income Statement And Earnings Preview - Part 3 (Notable MBS Price Decreases)

2018-10-10 seekingalpha
I am projecting AGNC will report a combined notable net unrealized loss on available-for-sale securities and investment securities measured at FMV for the third quarter of 2018.
NYMTO ORC FNMA CHMI NYMTP CIM AI TWO AGNC AIW WMC NRZ AIC CYS TRI MTGE MITT FMCKI FMCKJ FMCCO FMCCP FMCCM FMCCN MFO FMCCI DX NLY FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL ARR MFA FMCC HTS IVR NYMT FMCCS FMCCT

13
AGNC Investment's Q3 2018 Income Statement And Earnings Projection - Part 2 (Hedges Partially To The Rescue)

2018-10-09 seekingalpha
Fairly similar to the prior quarter, I am projecting AGNC will report a modest-notable gain regarding the company’s derivative instruments and other securities for the third quarter of 2018.
NYMTO ORC CHMI NYMTP AI TWO AGNC AIW NRZ AIC NLY CYS ARR NYMT

13
AGNC Investment's Q3 2018 Income Statement And Earnings Projection - Part 1 (Including Net Spread Trend)

2018-10-03 seekingalpha
This series projects AGNC’s income statement for the third quarter of 2018. These projections help readers understand how most of the fixed-rate agency mREIT sector performed (valuable insight).
NYMTO ORC CHMI NYMTP AI AGNC AIW MO NRZ AIC NLY CYS ARR HTS NYMT

16
Annaly Capital's Dividend And Valuation Compared To 19 mREIT Peers (Includes Q4 2018 And 2019 Dividend Projections) - Part 2

2018-09-24 seekingalpha - 1
This article compares NLY’s recent dividend per share rates, yield percentages, and several dividend sustainability metrics to 19 mREIT peers.
ANH NYMTO ORC CHMI NYMTP AI CIM CMO TWO AGNC AIW GPMT MO WMC NRZ AIC CYS 511505 CAPITALT MITT MFO DX NLY ARR BXMT MFA IVR NYMT

29
AGNC Investment And Orchid Island Capital: MBS Pricing For Q3 2018 (Recent Cautionary Trend)

2018-09-20 seekingalpha
Following continued requests by readers, this article analyzes fixed-rate agency MBS price movements during the third quarter of 2018 (through 9/14/2018).
NYMTO ORC FNMA CHMI NYMTP CIM AI TWO AGNC AIW MO WMC NRZ AIC CYS TRI MITT FMCKI FMCKJ FMCCO FMCCP FMCCM FMCCN MFO FMCCI DX NLY FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL ARR MFA FMCC IVR NYMT FMCCS FMCCT

32
This Giant 20% Yield Is Ripe For The Picking

2018-09-03 seekingalpha - 1
This ETN yields 20% based on recent prices. Investors are set to double their initial investment in less than 5 years.
CS STWD.WI FNMA FMCKI FMCKJ ABRN REM LADR TWO AGNC ABR FMCCO FMCCP FMCCM FMCCN NRZ FMCCI NLY FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK CYS FMCKL FMCC ABRN.CL STWD FMCCS FMCCT

17
Comparing Annaly Capital's BV, Dividend, And Valuation To 20 mREIT Peers (Post Q2 2018 Earnings) - Part 1

2018-08-15 seekingalpha - 2
Part 1 of this article compares NLY’s recent leverage, hedging coverage ratio, quarterly BV, economic loss, and current valuation to twenty mREIT peers.
ANH NYMTO ORC CHMI NYMTP CIM AI CMO TWO AGNC AIW GPMT MO WMC NRZ AIC CYS 511505 CAPITALT MITT MFO DX NLY ARR BXMT MFA IVR NYMT

30
Annaly Capital And Arlington Asset Investment: MBS Pricing For First Half Of Q3 2018 (Includes Current BV Projections)

2018-08-13 seekingalpha - 1
Following continued requests, this article analyzes fixed-rate agency MBS price movements during the third quarter of 2018 (through 8/10/2018).
NYMTO ORC FNMA CHMI NYMTP CIM AI TWO AGNC AIW MO WMC NRZ AIC CYS TRI MITT FMCKI FMCKJ FMCCO FMCCP FMCCM FMCCN MFO FMCCI DX NLY FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL ARR MFA FMCC IVR NYMT FMCCS FMCCT

4
CYS / CYS Investments, Inc. / BlackRock Inc. - null (Passive Investment)

2018-08-09 sec.gov
us12673a1088_080818.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) CYS INVESTMENTS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 12673A108 -------------------------------------------------------- (CUSIP Number) July 31, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover pa
CYS

4
CYS / CYS Investments, Inc. / BlackRock Inc. - null (Passive Investment)

2018-08-09 sec.gov
us12673a1088_080818.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) CYS INVESTMENTS INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 12673A108 -------------------------------------------------------- (CUSIP Number) July 31, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover pa
CYS

4
Two Harbors Investment Corp (TWO) CEO Thomas Siering on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Two Harbors Investment Corp (NYSE:TWO) Q2 2018 Earnings Conference Call August 8, 2018 9:00 AM ET
TWO FNMA CYS

16
Analyzing AGNC Investment's Results For Q2 2018 (Including August-October 2018 Dividend Projection)

2018-08-01 seekingalpha - 1
On 7/25/2018, AGNC reported results for the second quarter of 2018. AGNC reported comprehensive income of $148 million and a non-tangible BV as of 6/30/2018 of $19.68 per common share.
NYMTO ORC CHMI NYMTP AI CMO TWO AGNC AIW MO NRZ AIC CYS ARR BXMT 511505 NYMT CAPITALT

4
CYS / CYS Investments, Inc. S-8 POS

2018-07-31 sec.gov
S-8 POS As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. 333-189619
CYS

4
CYS / CYS Investments, Inc. POSASR

2018-07-31 sec.gov
POSASR As filed with the Securities and Exchange Commission on July 31, 2018 Registration No. 333-218161
CYS

4
CYS / CYS Investments, Inc. 8-K (Current Report)

2018-07-31 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
CYS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CYS / CYS Investments, Inc. on message board site Silicon Investor.

Encysive Pharmaceuticals (ENCY) Encysive Pharmaceuticals (ENCY) Encysive Pharmaceuticals (ENCY) CyberShop International, Inc. (CYSP) CyberShop International, Inc. (CYSP) CyberShop International, Inc. (CYSP)
CYSV: Cysive, Inc. CYSV: Cysive, Inc. CYSV: Cysive, Inc. Crys-Tel CYSS, PacRim PAKR, Metals Research MLRA, Au0026A ANAF Crys-Tel CYSS, PacRim PAKR, Metals Research MLRA, Au0026A ANAF Crys-Tel CYSS, PacRim PAKR, Metals Research MLRA, Au0026A ANAF
Cysive - CYSV Cysive - CYSV Cysive - CYSV Crys*Tel Telecommunications.com, Inc. (CYSS) Crys*Tel Telecommunications.com, Inc. (CYSS) Crys*Tel Telecommunications.com, Inc. (CYSS)
TOPS -- 50/50 partner with CYSP TOPS -- 50/50 partner with CYSP TOPS -- 50/50 partner with CYSP cysi - CYSI - CYBERFAST SYSTEM cysi - CYSI - CYBERFAST SYSTEM cysi - CYSI - CYBERFAST SYSTEM
CUSIP: 12673A108